Skip to content

Dr Rodrigo Motta

DNA Methylation in PSC and Bile Duct Cancer

Awarded to Dr Rodrigo Motta from the University of Oxford

 

The total grant awarded is £15,000

Duration of award: 1 year (March 2025 to March 2026)

Research title: DNA Methylation in PSC and Bile Duct Cancer

Dr Rodrigo Motta

Summary

PSC Support has awarded £15,000 to Dr Rodrigo Motta from the University of Oxford to look for non-invasive markers of cancer risk in people with PSC.

Dr Motta will do this by studying genetic changes in samples of blood and bile from people with PSC, using genome-wide DNA methylation and genotyping/sequencing technology. This will allow him to identify the patterns of changes that could be used as markers for the early diagnosis of bile duct cancer.

This is important because despite lots of promising research in this area, we still don’t have a reliable way to detect or predict who will get bile duct cancer, and early detection is critical for the best chance of successful treatment.

What will Dr Motta do?

Over the last 3 years the research team has been collecting blood and bile samples as part of the BRC4 Cancer Theme study, of which the ‘High-Risk cohort and Primary Liver Cancer’ theme is led by Dr Emma Culver. The samples have been stored under the Translational Gastroenterology and Liver Unit (TGLU) University of Oxford biobank.

Dr Motta will study:

  • Blood samples from:
    • 20 patients with PSC,
    • 20 patients with PSC and high-risk strictures ‘dominant strictures’ (defined by MRCP and followed up) and
    • 10 patients with PSC and signs of bile duct cancer.
  • Bile samples from:
    • 20 patients with PSC and high-risk strictures and
    • 10 patients with PSC and signs of bile duct cancer
    • 20 patients who don’t have PSC but do have non-cancerous bile duct damage. These are ‘control samples’.

This type of work is expensive, and Dr Motta’s team will also contribute some of their own research funds to do some of the methylation and genotyping analyses for the control samples.

DNA from the samples will be extracted at the TGLU laboratory and Dr Motta will then perform DNA methylation and genotype sequencing.

Why is this study important?

Dr Motta’s study is important because, despite lots of promising research in this area, we still don’t have a reliable way to screen for bile duct cancer in people with PSC. Although this cancer is rare, it is often diagnosed at a stage that is too late for effective treatment. Early identification is critical for the best chance of successful treatment.

Dr Motta’s approach is to study the patterns of noise (DNA myelination) in the blood and bile. This could reveal new markers of early bile duct cancer meaning that this cancer could be picked up and treated early, revolutionising routine monitoring for people with PSC.

We are leaving no stone unturned in our efforts to develop effective screening methods for bile duct cancer in people with PSC.

Progress Report

We collected and separated plasma samples from 100 patients between April and September 2025. These samples were divided in groups, namely

  • 20 cholangiocarcinoma (bile duct cancer, CCA) samples,
  • 20 PSC with high risk of CCA samples,
  • 20 PSC and low risk of CCA samples,
  • 20 ulcerative colitis samples and
  • 20 healthy controls.

These samples are going to be analysed using a new technology developed at the University of Oxford. This technology allows us to study changes around the DNA without damaging it too much, therefore even small samples (3mL) can give us plenty of information to look for early signs of cancer.

Dr Rodrigo Motta, October 2025

quote2

"With the grant from PSC support I am aiming to understand the different changes around the DNA (DNA methylation) of people with PSC who are at high risk of developing bile duct cancer and those who have cancer.

This is important because if we develop a better method to look for early signs of bile duct cancer, we can tailor our care to each person with PSC according to their own risk. Moreover, early detection of cancer significantly improves the chances of an effective treatment.

I am interested in PSC because it is a rare and complex disease; therefore, it requires that we collaborate with centres around the globe to understand and treat it better. The PSC community has outstanding people and the ability to work with them with a shared goal of improving the life of those with PSC motivates me greatly."

- Dr Rodrigo Motta

Mission 2030 is an ambitious challenge and we can’t do it alone. We need your help to find the breakthrough people with PSC so desperately need.

It’s time we found effective treatments for PSC

Play your part in leaving no stone unturned

Donate now

Mission 2030 - Help us fund £1 million of research by 2030

Fundraise for research

We need your support now

more than ever!

Make a donation to research and all the other things we do to help people affected by PSC


More research we've funded:

DNA Methylation for Cancer Risk in PSC

Bile Duct Cancer Detection

Characterising Genetic Changes in Bile Ducts

Understanding Fatigue in PSC

Simvastatin in PSC

Biological Markers from Machine Learning

Predicting Bowel Cancer Risk

Understanding Pregnancy in PSC

Developing a blood test to predict and detect bile duct cancer

Validating a Diagnostic Biomarker in Primary Sclerosing Cholangitis

Cell States in the Transition from PSC to Bile Duct Cancer

PSC and IBD Link

Dr Palak Trivedi – FARGO

Dr Goode Dr Rushbrook Diagnostic Biomarker

Dr Banales Early Diagnosis of Bile Duct Cancer

UK-PSC Project Manager

Dr Boulter – Non-canonical Wnt Signalling

West Midlands Virtual PSC Programme

Dr Guest – Biomarkers in PSC/biliary duct cancer

Dr Williamson – PIP-C Study

We are your voice

Your views make that voice stronger. #LetsBeatPSC

Make a difference

Help us fund PSC research and support people with PSC

Want to know more?

Receive regular info, tips and news on all things PSC